The Experimental Medicine and Rheumatology Group have had published today the results of their IMPROVE study in Lancet Haematology.
The IMPROVE study set out to investigate in those with chronic lymphocytic leukaemia (CLL) if having a 3-week pause in existing Bruton tyrosine kinase inhibitor (BTKi) therapy during COVID-19 vaccination - improved the immune response to the vaccination.
The results suggest that pausing BTKi around the time of vaccination is not beneficial for immunity and should not be recommended in clinical practice.
https://www.sciencedirect.com/science/article/pii/S2352302625000080